Lexicon Dec, 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

 Launch Preparations Actively Underway; Launch Planned for Early 2025

Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

https://www.globenewswire.com/news-release/2024/07/16/2913701/0/en/Lexicon-Pharmaceuticals-Receives-December-20-2024-PDUFA-Goal-Date-for-Sotagliflozin-Type-1-Diabetes-NDA-Resubmission.html